Andreas Polychronis

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Fabrice Barlési, Johan Vansteenkiste, David R. Spigel et al. · The Lancet Oncology · 2018 · 394 citations

Medicine, Metronomic Therapy, Clinical Trials +9

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

Andreas Polychronis, H D Sinnett, Dimitri Hadjiminas et al. · The Lancet Oncology · 2005 · 194 citations

Breast Oncology, Medicine, Gynecology +6

Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer

Ursula McGovern, Richard E. Francis, Barrie Peck et al. · Molecular Cancer Therapeutics · 2009 · 130 citations · Full text

The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells

Janna Krol, Richard E. Francis, André Albergaria et al. · Molecular Cancer Therapeutics · 2007 · 89 citations · Full text

Medicine and evidence: knowledge and action in clinical practice

Andrew Miles, Michael Loughlin, Andreas Polychronis · Journal of Evaluation in Clinical Practice · 2007 · 80 citations · Full text